Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 17/20 | 0.61 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508865 | 0.95 | FOLH1 (0.61) | FOLH1RIMKLANAALAD2GLP1R | |
| SCHEMBL19182223 | 0.94 | FOLH1 (0.65) | FOLH1RIMKLANAALAD2GLP1R | |
| SCHEMBL2742772 | 0.93 | FOLH1 (0.51) | FOLH1RIMKLANAALAD2GLP1R | |
| SCHEMBL15087055 | 0.93 | FOLH1 (0.51) | FOLH1RIMKLANAALAD2GLP1R | |
| SCHEMBL15003765 | 0.88 | FOLH1 (0.62) | FOLH1RIMKLANAALAD2GLP1R | |
| SCHEMBL15505809 | 0.87 | FOLH1 (0.57) | FOLH1RIMKLANAALAD2GLP1R | |
| SCHEMBL16518793 | 0.87 | FOLH1 (0.70) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL10134673 | 0.85 | FOLH1 (0.58) | FOLH1GLP1R | |
| SCHEMBL16256863 | 0.84 | FOLH1 (0.60) | FOLH1GLP1R | |
| SCHEMBL18655461 | 0.84 | FOLH1 (0.74) | FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8246968-B2 | Cancer cell targeting using nanoparticles | BIND BIOSCIENCES, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090061010-A1 | CANCER CELL TARGETING USING NANOPARTICLES | CD47, EPCAM, CD44 | FOLH1 279/4885RIMKLA 3697/4885NAALAD2 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.